Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sompo Asset Management Co. Ltd.

Sompo Asset Management Co. Ltd. lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 36,690 shares of the biopharmaceutical company’s stock after acquiring an additional 660 shares during the period. Sompo Asset Management Co. Ltd.’s holdings in Bristol-Myers Squibb were worth $1,883,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. AMG National Trust Bank raised its position in shares of Bristol-Myers Squibb by 1.0% during the 3rd quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock valued at $1,143,000 after buying an additional 201 shares during the period. Van ECK Associates Corp lifted its stake in shares of Bristol-Myers Squibb by 22.7% in the 3rd quarter. Van ECK Associates Corp now owns 451,615 shares of the biopharmaceutical company’s stock valued at $26,212,000 after purchasing an additional 83,599 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 3.5% during the 3rd quarter. HighTower Advisors LLC now owns 1,583,586 shares of the biopharmaceutical company’s stock worth $92,004,000 after purchasing an additional 53,664 shares during the period. Shepherd Financial Partners LLC increased its position in shares of Bristol-Myers Squibb by 19.1% during the 3rd quarter. Shepherd Financial Partners LLC now owns 11,070 shares of the biopharmaceutical company’s stock worth $643,000 after purchasing an additional 1,779 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in Bristol-Myers Squibb in the third quarter valued at about $84,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.5 %

Shares of NYSE:BMY traded up $0.60 on Friday, hitting $41.48. 13,665,456 shares of the company’s stock were exchanged, compared to its average volume of 14,074,232. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a 1-year low of $39.91 and a 1-year high of $66.38. The company has a market capitalization of $84.08 billion, a PE ratio of -13.38, a P/E/G ratio of 14.04 and a beta of 0.43. The firm’s 50-day moving average is $45.50 and its 200 day moving average is $48.98.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Wall Street Analyst Weigh In

BMY has been the subject of a number of recent analyst reports. Barclays dropped their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 23rd. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Finally, Wells Fargo & Company raised their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.